Upperton Pharma Solutions Completes Build of New Sterile Manufacturing Facility in Nottingham

• Upperton Pharma Solutions has completed the build of a new 7,000 sq. ft. sterile manufacturing facility in Nottingham, UK, designed in line with revised EU GMP Annex-1 regulations.

• The facility will support the manufacturing of small-volume aseptic and terminally sterilised liquids and powders, enhancing Upperton’s service offerings in clinical and late-stage manufacturing.

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO), has announced the completion of a new sterile manufacturing facility in Nottingham, UK. This addition complements the company’s existing 50,000 sq. ft. Trent Gateway site and is specifically designed to meet the revised EU GMP Annex-1 regulations for sterile drug product manufacturing.

The new 7,000 sq. ft. facility will support the production of aseptic and terminally sterilised small-volume liquids and powders, including formulations for parenteral, nasal, and pulmonary delivery. With the capability to handle batch sizes of up to 2,000 vials, pre-filled syringes, and cartridges, the facility will also support formulation development, clinical manufacturing, and analytical testing.

“This facility’s completion marks a significant milestone for Upperton,” said Nikki Whitfield, Chief Executive Officer. “Our leadership team’s experience in sterile facility builds ensures we are positioned as the partner of choice for small to mid-sized biotech and pharma companies seeking quick access to sterile manufacturing services.”

Equipped with two cleanrooms featuring advanced VHP isolation technology, the facility will be used for GMP manufacturing of sterile drug products, integrating full-service formulation development and quality control laboratories. The expansion aligns with Upperton’s continued commitment to supporting drug developers with high-quality services, from early-stage development to clinical trials and late-stage manufacturing.

As commissioning and equipment installation progress, Upperton Pharma Solutions will leverage its existing R&D and analytical teams to provide pre-formulation and stability studies for early proof-of-concept products in parenteral, nasal, and pulmonary delivery.